Azenta (Azenta) Total Current Assets : $1,382.8 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Azenta Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Azenta's total current assets for the quarter that ended in Dec. 2023 was $1,382.8 Mil.

Azenta Total Current Assets Historical Data

The historical data trend for Azenta's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Total Current Assets Chart

Azenta Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Current Assets

Get a 7-Day Free Trial

647.15

649.45

777.37

2,459.35

1,418.96

Azenta Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															1,619.98	1,585.73	1,510.84	1,418.96	1,382.80

Azenta Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Azenta's Total Current Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1017.783	+	156.535	+	128.198	+	116.44
	=	1,419.0

Azenta's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	984.135	+	155.926	+	127.184	+	115.556
	=	1,382.8

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Azenta (NAS:AZTA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Azenta's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	984.135	-	380.65	+	0.75 * 155.926	+	0.5 * 127.184
=	784.0

Azenta Total Current Assets Related Terms

Thank you for viewing the detailed overview of Azenta's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Azenta (Azenta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Executives

Herman Cueto	officer: EVP, Chief Financial Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes	officer: VP, Chief Accounting Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray	officer: Chief Strategy & New Business	C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin	director
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne	officer: SVP and GM, Life Sciences Proj	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou	officer: SVP and General Manager, Genom	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus	officer: EVP & Chief Operating Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson	officer: EVP & Chief Financial Officer	C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley	officer: Chief Human Resources Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram	officer: VP, Finance & Corp. Controller	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De	officer: Chief Commercial Officer, LS	15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka	officer: Sr. VP, General Manager	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha	officer: SVP, GM BLS-Products	15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824